Incidence of four major osteoporotic fragility fractures among older individuals in Sado, Japan, in 2020

J Bone Miner Metab. 2024 Nov;42(6):647-652. doi: 10.1007/s00774-024-01529-z. Epub 2024 Jul 8.

Abstract

Introduction: This study compared the 2020 incidence of fragility fractures in Sado City with those from 2004 to 2015.

Materials and methods: Data from patients aged ≥ 60 years living in Sado City with fragility fractures in the hip, vertebral, distal radius, and proximal humerus between January 1 and December 31, 2020, were collected. We examined the number and incidence of four types of osteoporotic fractures in the older population aged ≥ 60 years living in Sado City in 2020. We compared the results with those of the 2004, 2010, and 2015 surveys, examining the temporal change and trend in the incidence of the four fracture types in this population. We investigated the use rate of anti-osteoporotic medications and the relationship between their administration and the occurrence of fragility fractures.

Results: The age-specific incidence of hip fractures slightly decreased from 2015. However, the incidence of the other three fractures slightly increased, although the difference was not statistically significant. The incidence of hip fractures markedly increased in the 80 s. In 2020, the percentage of patients taking anti-osteoporotic agents before the occurrence of fractures decreased to 12.4% from 14.5% in 2015; it increased from 4% in 2004 to 7.6% in 2010.

Conclusion: The 2020 incidence of the four fractures did not decrease, and the percentage of patients receiving anti-osteoporotic agents did not increase. A higher frequency of osteoporosis treatment is necessary to reduce the incidence of fragility fractures. We recommend using anti-osteoporotic agents to prevent hip fractures among individuals in their mid-70 s and above.

Keywords: Distal radius fracture; Hip fracture; Humerus fracture; Incidence; Vertebral fracture.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Bone Density Conservation Agents / therapeutic use
  • Female
  • Hip Fractures* / epidemiology
  • Humans
  • Incidence
  • Japan / epidemiology
  • Male
  • Middle Aged
  • Osteoporosis / drug therapy
  • Osteoporosis / epidemiology
  • Osteoporotic Fractures* / epidemiology
  • Spinal Fractures / epidemiology

Substances

  • Bone Density Conservation Agents